Market Research Logo

Oral Mucositis - Pipeline Review, H2 2015

Oral Mucositis - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Oral Mucositis - Pipeline Review, H2 2015’, provides an overview of the Oral Mucositis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Oral Mucositis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Oral Mucositis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Oral Mucositis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Oral Mucositis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Oral Mucositis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Oral Mucositis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Oral Mucositis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Oral Mucositis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Oral Mucositis Overview
Therapeutics Development
Pipeline Products for Oral Mucositis - Overview
Pipeline Products for Oral Mucositis - Comparative Analysis
Oral Mucositis - Therapeutics under Development by Companies
Oral Mucositis - Therapeutics under Investigation by Universities/Institutes
Oral Mucositis - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Oral Mucositis - Products under Development by Companies
Oral Mucositis - Products under Investigation by Universities/Institutes
Oral Mucositis - Companies Involved in Therapeutics Development
Aldeyra Therapeutics, Inc.
Cellceutix Corporation
Clevexel Pharma SAS
Colby Pharmaceutical Company
Daewoong Pharmaceutical Co., Ltd.
Intrexon Corporation
Laila Pharmaceuticals Pvt. Ltd.
Onxeo SA
Otsuka Holdings Co., Ltd.
ProCertus BioPharm Inc.
Soligenix, Inc.
Spectrum Pharmaceuticals, Inc.
Sucampo Pharmaceuticals, Inc.
Oral Mucositis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AG-013 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AP-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AP-002 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
brilacidin tetrahydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
clonidine hydrochloride ER - Drug Profile
Product Description
Mechanism of Action
R&D Progress
cobiprostone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CVXL-0095 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
dusquetide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GC-4403 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GC-4419 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gene Therapy for Oral Mucositis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
JVRSOD - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LP-00409 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
nepidermin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NS-2 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OralX - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pralatrexate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rebamipide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Regenasyn - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Oral Mucositis - Recent Pipeline Updates
Oral Mucositis - Dormant Projects
Oral Mucositis - Discontinued Products
Oral Mucositis - Product Development Milestones
Featured News & Press Releases
Aug 03, 2015: Cellceutix Announces Ongoing Enrollment of Phase 2 Trial of Brilacidin for Oral Mucositis
Jun 18, 2015: Onxeo Consolidates Its Industrial Property with a US Patent Protecting Validive until 2029
Jun 01, 2015: Enrollment in Cellceutix Phase 2 Clinical Trial of Brilacidin-OM For Oral Mucositis Expanding to Additional Centers
May 26, 2015: Onxeo Announces Final Data from Completed Phase II Trial of Validive for the Prevention of Severe Oral Mucositis in Head and Neck Cancer Patients
May 07, 2015: FDA Grants Fast Track Designation to Sucampo's Cobiprostone for Oral Mucositis
May 06, 2015: Oral Presentation of Phase II Trial Results of Validive at the MASCC/ISOO International Symposium
Apr 23, 2015: Aldeyra Therapeutics Abstract Accepted for Presentation at the 2015 Multinational Association of Supportive Care in Cancer - International Society of Oral Oncology Annual Meeting
Apr 02, 2015: Phase II trial results of Validive presented at the ASCO Conference
Mar 03, 2015: Soligenix Announces Positive Recommendation by Data Review Committee on its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients
Jan 05, 2015: Soligenix Announces Positive Preliminary Nonclinical Results in Macrophage Activation Syndrome
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Oral Mucositis, H2 2015
Number of Products under Development for Oral Mucositis - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Investigation by Universities/Institutes, H2 2015
Oral Mucositis - Pipeline by Aldeyra Therapeutics, Inc., H2 2015
Oral Mucositis - Pipeline by Cellceutix Corporation, H2 2015
Oral Mucositis - Pipeline by Clevexel Pharma SAS, H2 2015
Oral Mucositis - Pipeline by Colby Pharmaceutical Company, H2 2015
Oral Mucositis - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2015
Oral Mucositis - Pipeline by Intrexon Corporation, H2 2015
Oral Mucositis - Pipeline by Laila Pharmaceuticals Pvt. Ltd., H2 2015
Oral Mucositis - Pipeline by Onxeo SA, H2 2015
Oral Mucositis - Pipeline by Otsuka Holdings Co., Ltd., H2 2015
Oral Mucositis - Pipeline by ProCertus BioPharm Inc., H2 2015
Oral Mucositis - Pipeline by Soligenix, Inc., H2 2015
Oral Mucositis - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2015
Oral Mucositis - Pipeline by Sucampo Pharmaceuticals, Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Oral Mucositis Therapeutics - Recent Pipeline Updates, H2 2015
Oral Mucositis - Dormant Projects, H2 2015
Oral Mucositis - Dormant Projects (Contd..1), H2 2015
Oral Mucositis - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Oral Mucositis, H2 2015
Number of Products under Development for Oral Mucositis - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report